FINAL PROGRAMME

(all times cest)

OCTOBER 6

WHAT WE HAVE 

update on state of the art

12.30 - 12.40 W0A0: Welcome and opening remarks Sara Montagnese (Italy) and Paolo Angeli (Italy)

SESSION 1: Basic science in hepatic encephalopathy

chaired by Sharon DeMorrow (USA) and Christopher Rose (Canada)

12.40 - 13.00 S1A1: The role of ammonia in progression of fibrosis in liver disease Rocío Gallego-Duran (Spain)

13.00 - 13.20 S1A2: Interaction between hyperammonaemia and glutamate, glutamine and GABA Andrea Cabrera-Pastor (Spain)

13.20 - 13.40 S1A3: Brain oedema in persistent hepatic encephalopathy Cristina Cudalbu (Switzerland)

13.40 - 14.00 S1A4: The impact of obesity on neurological decline in experimental cirrhosis Rafael Ochoa-Sanchez (Canada)

14.00 - 14.30 BREAK

SESSION 2: Hepatic encephalopathy diagnosis

chaired by Karin Weissenborn (Germany) and Olivero Riggio (Italy)


14.30 - 14.50 S2A1: Cognitive dysfunction in NAFLD – a new hepatic encephalopathy? Karen Louise Thomsen (Denmark)
14.50 - 15.10 S2A2: Ammonia – applications and pitfalls  Dominique Thabut (France)
15.10 - 15.30 S2A3: The neuropsychology of metabolic encephalopathies Nicolas Weiss (France)
15.30 - 15.50 S2A4: Diabetes (and sleep apnoea) — how do they interact with MHE and MHE diagnostic tools Christian Labenz (Germany)

15.50 - 16.20 BREAK
 

SESSION 3: Hepatic encephalopathy treatment

chaired by Jasmohan Bajaj (USA) and Piero Amodio (Italy)

16.20 - 16.40 S3A1: Potassium and sodium – innocent bystanders or active contributors to HE  Niels Kristian Agaard (Denmark)
16.40 - 17.00 S3A2: HE and the gut – how far are we from clinical use? Debbie Shawcross (UK)
17.00 - 17.20 S3A3: Prevention of post-TIPS HE – nutrition, medication or more careful patient selection? Silvia Nardelli (Italy)
17.20 -17.40  S3A4: Closing portosystemic shunts – does it work, and which should we target? Wim Laleman (Belgium)

17.40 - END

OCTOBER 7

WHAT IS HAPPENING 

young researchers and short oral communications

SESSION 4: Basic science: Oral abstracts and short oral communications

chaired by Dieter Haussinger (Germany) and Cristina Cudalbu (Switzerland)

12.30 - 12.45 S4B1: Rescuing the brain from non-alcoholic fatty liver disease: role of the monocarboxylate transporter-1  Anna Hadjihambi  (UK)
12.45 - 13.00 S4B2: Cognitive dysfunction is associated with systemic inflammation and neuroinflammation in a rodent model of NASH 
                                              Anne Catrine Daugaard Mikkelsen (Denmark)
13.00 - 13.05 S4B3: Central Nervous System Oxidative Stress and Inflammation in a rat model of Type C Hepatic Encephalopathy – brothers in arms? 
                                        
Katarzyna Pierzchala (Switzerland)

13.05 - 13.10 S4B4: Sex Disparity on the development of HE: impact of ammonia and ROS in the development of brain edema and hepatic encephalopathy severity in BDL rats

                                             Mariana Oliveira (Canada)
13.10 - 13.15 S4B5: Hyperammonemia in type c he induces a scenescent-like phenotype in neurons Elaina Williams (USA)

13.15 - 13.30 BREAK

SESSION 5: HE Diagnosis: Oral abstracts and short oral communications 

chaired by German Soriano (Spain) and Marsha Morgan (UK)

13.30 - 13.45 S5B1: Neuropsychological assessment of hepatic encephalopathy and its contribution to differential diagnosis in a multidisciplinary evaluation of

                                     patients with chronic liver disease Lyès  Kheloufi  (France)
13.45 - 14.00 S5B2: Impaired cognition in morbid obesity is not specifically linked to fatty liver and liver fibrosis severity Lea Grønkjær  (Denmark)
14.00 - 14.15 S5B3: Characterizing sensory and autonomic dysfunction in cirrhotic patients with minimal hepatic encephalopathy Dalia Rega (Spain)
14.15 - 14.20 S5B4: Working memory in patients with varying degree of hepatic encephalopathy (HE): an EEG-fNIRS study Lisa Zarantonello (Italy)
14.20 - 14.25 S5B5: Preliminary data on Animal Naming Test in healthy Danes and patients with liver cirrhosis Mette Lauridsen (Denmark) 
14.25 - 14.30 S5B6: Brain energy metabolism is altered in patients with posttransplant enecephalopathy after liver transplantation Henning Pflugrad 
(Germany)

14.30 - 15.00 BREAK

SESSION 6: HE Treatment: Oral abstracts and short oral communications 

chaired by Radha Dhiman (India) and Manuela Merli (Italy)

15.00 - 15.15 S6B1: Pre-emptive TIPS should be performed in high-risk cirrhotic patients with variceal bleeding despite the presence of HE at admission

                                     Marika Rudler (France)
15.15 - 15.30 S6B2: An Electronic Decision Support Intervention Reduces Readmissions for Patients with Cirrhosis Jeremy Louissaint (USA)
15.30 - 15.45 S6B3: Efficacy and safety of albumin infusion for overt hepatic encephalopathy: A systematic review and meta-analysis Eugene Wong Yu Jun (Singapore)
15.45 - 15.50 S6B4: Effect of Fecal Microbiota Transplant on Hepatic Encephalopathy Varies by Donor and Recipient Factors Patricia Bloom (USA)
15.50 - 15.55 S6B5: The rate of successful extubation in mechanically ventilated patients with cirrhosis and hepatic coma Jeffrey Gibbs (USA)
15.55 - 16.00 S6B6: In vitro evaluation of novel urease inhibitors for the treatment of hepatic encephalopathy  Diana Evstafeva  (Switzerland)

16.00 - 16.15 S6B7: Session summary by Christopher Rose (Canada) and Mette Lauridsen (Denmark) 
16.15 - 16.30 BREAK for poster and abstract scoring
16.30 - 17.00 Tour of the Padova University Hall in celebration of its 800 years

17.00 - 17.30 General Assembly (ISHEN members)

17.30 - END

OCTOBER 8

WHAT WE NEED 

a look to the near future of HE prognostication, diagnosis, and treatment

SESSION 7: The future in hepatic encephalopathy basic science 

chaired by Vicente Felipo (Spain) and Mark Swain (Canada)

12.30 - 12.50 S7C1: Mitochondrial dysfunction in hepatic encephalopathy Marta Méndez (Spain)
12.50 - 13.10 S7C2: Astrocytes and microglia to the pathogenesis of hepatic encephalopathy Matthew McMillin (USA)
13.10 - 13.30 S7C3: The role of extracellular vesicles in the induction of neuroinflammation in hepatic encephalopathy Paula Izquierdo-Alterejos (Spain) 

13.30 - 13.50 S7C4: Altered Brain Lactate Metabolism in HE Anna Hadjihambi (UK) 

13.50 - 14.00 SHORT BREAK

 

SESSION 8: The future for hepatic encephalopathy diagnosis 

chaired by Barjesh Sharma (India) and Manuel Romero-Gomez (Spain)

 

14.00 - 14.20 S8C1: Prediction of future OHE beyond psychometric testing Elliot Tapper (USA)
14.20 - 14.40 S8C2: Machine learning in MHE diagnosis - will it be possible? Esmaeil Nadimi (Denmark)
14.40 - 15.00 S8C3: Biomarkers in MHE diagnosis and OHE prediction - blood and breathomics James Covington and Ramesh Arasaradnam (UK)
15.00 - 15.20 S8C4: Remote monitoring of cognition in HE – what are the options? Russell Rosenblatt (USA)

15.20 - 15.40 BREAK
 

SESSION 9: The future in hepatic encephalopathy treatment 

chaired by Rajiv Jalan (UK) and Rob Rahimi (US)

15.40 - 16.00 S9C1: Neurosteroids in HE – potential treatment targets? Torbjörn Bäckström (Sweden)
16.00 - 16.20 S9C2: Pharmaceutical prevention of OHE - what’s the evidence? Lise Lotte Gluud (Denmark)
16.20 - 16.50 S9C3: Andrés Blei Lecture by Vicente Felipo (Spain)
: Hyperammonemia and peripheral inflammation induce neuroinflammation that alters neurotransmission and cognitive and motor function in HE: underlying mechanisms and therapeutic implications
16.50 - 17.00 SHORT BREAK

Wrap up

 

17.00 - 17.15 W1A1: Announcement of the winner of the Juan Córdoba Young Investigator Award for best oral presentation and the winner of best poster 
17.15 - 17.30 W1A2: Closing remarks by the president and a look towards the next symposium by the president elect Prof. Karin Weissenborn, Hannover Medical School, Germany 

17.30 - END